Cardiovascular toxicity of anticancer drugs: the dark side of success

Cancer represents the second cause of death in European Union after cardiovascular diseases, accounting for 27% all deaths. Anticancer drugs (ACDs) have poor cell selectivity and a narrow therapeutic margin, such way that small increases their plasma levels lead to appearance adverse reactions multiple tissues. The FACs can produce wide range (named cardiotoxicity) increase morbidity even some patients whose cancer has been cured by ACD. risk cardiotoxicity with age, since up two-thirds are older than 65 years cancer, diseases incidence age CAD-induced will coexist this population. diagnosis, prognosis, follow-up, treatment induced CAFs represent challenge daily clinical practice makes teamwork among cardiologists, oncologists, hematologists essential. recent guidelines on cardio-oncology Society Cardiology first experience joint work comprehensively address due anticancer drugs.